BillionToOne utilizes proprietary Quantitative Counting Templates (QCTs™) to detect and quantify disease-related DNA fragments at single base-pair resolution from cell-free DNA. This technology enables precise prenatal screening for recessive conditions and aneuploidies, addressing the need for accurate risk assessment from a simple maternal blood draw.
Funding
$425.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+11Founders
Product
Problem
Traditional prenatal screening methods for recessive conditions and aneuploidies often lack the resolution to detect subtle genetic variations from cell-free DNA, potentially leading to inaccurate risk assessments. Current technologies may not precisely quantify disease-related DNA fragments, impacting the reliability of prenatal testing.
Solution
BillionToOne offers a molecular diagnostics platform leveraging Quantitative Counting Templates (QCTs™) to enhance the detection and quantification of disease-related DNA fragments at single base-pair resolution from cell-free DNA. This technology enables precise non-invasive prenatal screening (NIPS) for recessive conditions and aneuploidies through a standard maternal blood draw. The UNITY Screen™ employs QCTs to provide a comprehensive carrier screen, single-gene analysis for recessive conditions, and aneuploidy screening, eliminating the need for a paternal sample. BillionToOne's approach improves the accuracy of fetal risk assessment, offering clinicians and expectant parents more reliable insights into potential genetic conditions. The QCT technology's ability to quantify minute genetic variations in cell-free DNA also has applications in liquid biopsy for oncology, enabling early and precise disease detection and monitoring.
Target Audience
The primary target audience includes obstetricians, gynecologists, maternal-fetal medicine specialists, and oncologists seeking advanced and precise diagnostic tools for prenatal screening and oncology testing.
Features
- Quantitative Counting Templates (QCTs™) for single base-pair resolution analysis of cell-free DNA
- UNITY Screen™ for comprehensive prenatal screening, including carrier screening, single-gene analysis, and aneuploidy detection
- Non-invasive prenatal screening (NIPS) using only a maternal blood draw
- Northstar Select™ to determine the most appropriate first-line therapy in oncology
- Northstar Response™ to monitor the effectiveness of cancer therapy